*Approved for use for CCTA in adults and pediatric patients 12 years and older. *Safety and efficacy have not been established in pediatric patients less than 12 years for CCTA. *Pediatric patients at higher risk of experiencing an adverse reaction during and after administration of any contrast agent may include those with asthma, hypersensitivity to other medication and/or allergens, cyanotic and acyanotic heart disease, congestive heart failure, or a serum creatinine greater than 1.5 mg/dL. Pediatric patients with immature renal function or dehydration may be at increased risk for adverse events due to slower elimination of iodinated contrast agents. *Information on safety, and dosing. *New indication.
|